Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage

Michael H Lehmann¹,²*, Philip JR Price¹,², Christine Brandmüller¹ and Gerd Sutter¹,²

Abstract

Background: The orthopoxvirus strain Modified Vaccinia virus Ankara (MVA) rapidly induces innate immune responses. Previously, we demonstrated that CCL2 and CCR1 are important players in MVA induced recruitment of leukocytes to the lung. Alveolar macrophages are sentinel cells in the lung, which are likely amongst the first cells of the immune system to encounter and respond to virus during respiratory infection. Therefore we examined the potential of the murine alveolar macrophage MH-S cell line as a model to study chemokine expression during infection with MVA and vaccinia virus (VACV) strain Western Reserve (WR).

Findings: MVA but not VACV infected MH-S cells increased the expression of the CXCR2 acting chemokine CXCL2. MH-S cells constitutively produced CCL2 and CCR1 acting chemokines CCL3, CCL5 and CCL9. Consequently, supernatants of mock treated and virus infected MH-S cells induced chemotaxis of murine promyelocyte MPRO cells and human monocytic THP-1 cells at the same level. However, supernatants of MVA infected MH-S cells significantly increased chemotaxis of the CCR2 deficient human monocytic cell line U-937. Chemotaxis of all three cell types was inhibited by J 113863, a CCR1 antagonist. Additionally, we show that MVA but not VACV WR infection of THP-1 cells induces expression of C-C motif and C-X-C motif chemokines and generates a chemotactic activity for monocytes, which was J 113863 sensitive.

Conclusions: These results extend our previous findings, demonstrating that MVA but not VACV WR induces chemokine production in alveolar macrophages and monocytes, which can induce recruitment of monocytes in a CCR1 dependent manner.

Keywords: Alveolar macrophage, CCR1, Chemotaxis, CXCR2, MH-S, MPRO, MVA, Neutrophil, THP-1, U937

Findings

Highly attenuated, replication deficient vaccinia strains such as Modified Vaccinia virus Ankara (MVA) are increasingly used as viral vectors for the development of new vaccines. Intranasal inoculation is an attractive route of vaccination for delivery of MVA to mucosal tissue in the respiratory tract, which was found to be both safe and immunogenic in a phase I clinical trial [1]. A distinguishing feature of MVA is its ability to activate a robust innate immune response [2-4]. We recently showed that MVA triggers the production of chemokines in primary lung fibroblasts and bone marrow derived macrophages (BMDM) which induce chemotaxis of neutrophils [5].

Alveolar macrophages (AM) are permanent residents of the lung which are capable of exerting both pro- and anti-inflammatory immune responses. Due to their presence on the luminal surface of the respiratory system AM are likely amongst the first cells to encounter virus after respiratory infection. Indeed, it has been shown that AM help to control VACV infection, and their depletion exacerbates the host inflammatory response to viral infection, which is probably due to the increased viral burden [6]. However little is known about the early immune responses that is elicited in AM upon encounter with VACV or highly attenuated strains such as MVA. Activation of AM is tightly regulated by the local microenvironment, cell-cell interactions and soluble mediators that

* Correspondence: Michael.Lehmann@lmu.de
1Institute for Infectious Diseases and Zoonoses, Ludwig-Maximilians-Universität München, Munich, Germany
2German Centre for Infection Research (DZIF), Partner site, Munich, Germany

© 2015 Lehmann et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
inhibit activation of pro-inflammatory signalling pathways, and removal of these signals leads to spontaneous activation of AM [7]. Consequently, our attempts to investigate cytokine expression in AM ex-vivo were largely unsuccessful due primarily to strong cytokine production in non-infected cells and rapid cell death of infected cells after isolation by bronchoalveolar lavage (data not shown). Therefore we tested the immortalized murine alveolar macrophage MH-S cell line [8] as a model system for MVA induced chemokine expression.

To determine whether MH-S cells are permissive to vaccinia virus infection and gene expression, cells were infected with MVA expressing the green fluorescent protein (GFP) under control of the P7.5 early/late promoter [9], and analysed using a MACSQuant VYB flow cytometer (Miltenyi Biotec). This showed that MH-S cells are readily infected with MVA and are permissive to viral gene expression (Figure 1A). Analysis by RT-PCR and ELISA showed that the CXCR2 ligand CXCL2 was induced by MVA but not by VACV WR in MH-S cells confirming our previous finding in primary murine lung fibroblasts [5]. Increased mRNA and protein levels of CXCL2 were detected at 8 h p.i., and the amount of CXCL2 produced depended on the MOI applied (Figure 1B, C and D). CXCL1 was only induced by LPS in MH-S cells, whereas CXCL5/6 (GCP-2/LIX), another neutrophils attracting chemokine [10], was not. Functionality of the GCP-2 specific PCR was demonstrated using RNA from murine alveolar epithelial MLE-12 cells treated with LPS or with supernatant from LPS challenged MH-S cells (Additional file 1).

Recently, we showed that CCR1 plays an important role in the recruitment of CD11b+Ly6C<hi> inflammatory monocytes into the lung [5]. Monocytes express the chemokine receptor CCR2 [11], and CCL2, a ligand for this receptor, has been shown to be important for MVA induced monocyte migration in vitro and in vivo [12]. However, monocytes are a heterogeneous population,
and some subsets do not express CCR2 [13]. Moreover, CCR1 expression is up-regulated on differentiating monocytes, leading to increased sensitivity to CCR1 ligands whilst simultaneously decreasing sensitivity to CCR2 ligands [14]. Consequently, we asked whether CCR1 also plays a role in mediating MVA triggered monocyte chemotaxis.

Unfortunately, the CCR1 ligands CCL3, CCL5 and CCL9, as well as the CCR2 ligand CCL2, were constitutively expressed in MH-S cells, and the levels were not increased by MVA or VACV WR infection (Figure 1B and C). Consequently, chemotaxis of murine promyelocyte MPRO cells was increased by supernatants from mock and virus infected MH-S cells to a similar level and decreased when MPRO cells were pre-incubated with the CCR1 antagonist J 113863 (Figure 2). Supernatants from LPS challenged MH-S cells induced less chemotaxis as compared to supernatants from mock infected cells. A possible explanation is that LPS-induced interleukin-10 in MH-S cells may have decreased the constitutive protein production of the C-C motif chemokines in a negative autocrine feedback loop [15,16].

To avoid the masking effect of CCL2 when investigating MVA for its potential to induce a CCR1 dependent chemotactic activity in cells of the monocyte/macrophage lineage we took advantage of the human monocytic cell line U-937, which, under our cell culture conditions, did not express CCR2 in contrast to human monocytic THP-1 cells (Figure 3A and B) [17]. Firstly,
we tested whether supernatants from MH-S cells are also capable of inducing chemotaxis of THP-1 cells. This was possible since human chemokine receptors CCR1 and CCR2 can also be activated by the relevant murine ligands [18-20]. As with MPRO cells, supernatants from mock and virus infected MH-S cells increased chemotaxis of THP-1 at a similar level, which was decreased when THP-1 cells were pre-incubated with J 113863 (Figure 3D, left panel). Supernatants from MVA infected MH-S cells increased the chemotaxis of U-937 cells compared to supernatants from mock infected and VACV WR infected MH-S cells. Importantly, this chemotaxis of U-937 cells was significantly reduced when U-937 cells were pre-incubated with J 113863 (Figure 3D, right panel). Of note, J 113863 also acts on human CCR3 but this receptor was not expressed in either cell line (Figure 3B). Interestingly, despite the constitutive expression of CCR1 ligands by MH-S cells, levels of chemotaxis of U-937 towards culture supernatants of mock-infected cells were only slightly increased as compared to medium control (Figure 3D). This potentially indicates that other mechanisms induced by MVA may be required for optimal induction of cell migration.

In a recent study, we showed that complement component C5 is required for respiratory recruitment of neutrophils during MVA infection [21]. Surprisingly, complement component C3 was not necessary, which suggests the activation of an unknown proteolytic process by MVA. Indeed, CCL3 is N-terminally processed by CD26/dipeptidyl peptidase IV converting it to a very potent CCR1 ligand [22]. Taken together, in future studies it would be interesting to investigate whether an MVA activated protease plays a role in MVA triggered recruitment of monocytes and neutrophils.

Previously we showed that MVA, but not VACV strain Elstree, induces chemokine expression including CCR1 acting chemokines in THP-1 cells [12]. Here we confirm our previous finding using multiprobe ribonuclease protection assay (RPA) and RT-PCR. Additionally we demonstrated that VACV WR does not induce chemokine expression in THP-1 cells (Figure 4A) and that supernatants from MVA but not VACV WR infected human monocytic THP-1 cells significantly increase chemotaxis of both naïve THP-1 cells and U-937 cells as compared to supernatants from mock infected cells (Figure 4B). As a side note, treatment of cells with the CCR1 antagonist

---

Figure 4 MVA, but not VACV WR, induces chemokine production in THP-1 cells and increases chemotaxis of monocytes in a CCR1 dependent manner. A) Total RNA from MVA or VACV WR infected THP-1 cells were isolated 6 hours p.i. and investigated subsequently by multiprobe ribonuclease protection assay using hCK-5 as probe (upper panel) and specific RT-PCR as indicated (lower panel). B) Chemotaxis of THP-1 cells (upper panel) and U-937 cells (lower panel) toward control medium (CM) and culture supernatants from THP-1 cells infected with MVA or VACV WR at 1 MOI for 16 hours. Where indicated, cells were treated with 5 nM of CCR1 antagonist J 113863 or the equivalent amount of solvent (all other samples) before running the assay as described in Figure 3. Data are means ± SD (n = 4). *, P < 0.05. ***, P < 0.001.
Additional file

Additional file 1: Verification of RT-PCR for murine CXCL5/GCP-2/LIX. As indicated, MLE-12 cells were challenged with LPS (1 μg/ml), with supernatants from MH-S cells (snMH-S) or with supernatants from LPS-treated MH-S cells (snMH-S-Thal) for six hours and subsequently lysed for total RNA isolation. RNA was converted in cDNA and amplified using forward primer 5′-cattgctgtgtagcagacgtc-3′ and reverse primer 5′-atacatattcggccagaca-3′. Primers were designed using NCBI Reference Sequence: NM_009141.3; Mus musculus chemokine (C-X-C motif) ligand 5 (Cxcl5), mRNA. The CXCL5/GCP-2/LIX PCR product corresponded with the expected size of 617 bp. RT-PCR for murine GAPDH was performed as described (5). PCR without cDNA served as negative control. Lambda DNA Hind III/phiX174 DNA Hae III was used as molecular weight marker (MWM).

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

This study was supported by the German Center for Infection Research (DJIF; TTU 07.803; MPRO cells were kindly provided by Dr. Adelheid Cerwenka (Deutsches Krebsforschungszentrum) and MH-S cells were kindly provided by Stephanie Konrad (Medical School Hannover).

Received: 6 October 2014 Accepted: 29 January 2015

Published online: 12 February 2015

References

1. Satti I, Meyer J, Harris SA, Thomas ZR, Griffiths K, Antrobus RD, et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14:933–46.
2. Royo S, Sainz Jr B, Hernandez-Jimenez E, Reyburn H, Lopez-Collazo E, Guerra S. Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses. J Virol. 2014;88:5511–23.
3. Dai P, Wang W, Cao H, Avogadri F, Dai L, Drexler X, et al. Modified Vaccinia virus Ankara triggers type 1 IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathway. PLoS Pathog. 2014;10:e1003989.
4. Price PJ, Torres-Dominguez LE, Brandmuller C, Suter G, Lehmann MH. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling. Vaccine. 2013;31:4231–4.
5. Price PJ, Luckow B, Torres-Dominguez LE, Brandmuller C, Zorn J, Kirschning CJ, et al. Chemokine (C-C Motif) Receptor 1 Is Required for Efficient Recruitment of Neutrophils during Respiratory Infection with Modified Vaccinia Virus Ankara. J Virol. 2014;88:10940–50.
6. Rivera R, Hutchens M, Luker KE, Sonstein J, Curtis JL, Luker GD. Murine alveolar macrophages limit replication of vaccinia virus. Virology. 2007;363:48–58.
7. Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol. 2008;9:1074–83.
8. Mbawuleke IN, Herscowitz HB, MH-S, a murine alveolar macrophage cell line: morphological, cytotoxic, and functional characteristics. J Leukoc Biol. 1989;46:119–27.
9. Staib C, Lowel M, Erfe V, Suter G. Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques. 2003;34:694–6, 698, 700.
10. Proost P, De Wolf-Peeters C, Conings R, Opdenakker G, Billiau A, Van Damme J. Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. J Immunol. 1993;150:1000–10.
11. Mack M, Cihak J, Simons C, Luckow B, Proudfoot AE, Plachy J, et al. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol. 2001;166:6497–704.
12. Lehmann MH, Kastenmuller W, Kandemir JD, Brandt F, Suezer Y, Sutter G. Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol. 2009;83:2540–52.
13. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2003;3:585–64.
14. Kaufmann A, Salentin R, Gema S, Sprenger H. Increase of CCR1 and CCR5 expression and enhanced functional response to MIP-1alpha during differentiation of human monocytes to macrophages. J Leukoc Biol. 2001;69:248–52.
15. Meng A, Zhang X, Shi Y. Role of p38 MAPK and STAT3 in lipopolysaccharide-stimulated mouse alveolar macrophages. Exp Ther Med. 2014;8:1772–6.
16. Berkman N, John M, Roessens G, Jose PJ, Barnes PJ, Chung KF. Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages. J Immunol. 1995;155:4412–8.
17. Lehmann MH, Wasianetz S, Kramer S, Erfe V, HiV-1 Nef upregulates CCL2/MCP-1 expression in astrocytes in a myristoylation- and calmodulin-dependent manner. J Cell Sci. 2006;119:5290–30.
18. Gadue RP, Cole SH, Roach ML, Tylaska LA, Nelson RT, Shepard RM, et al. DNA and RNA virus Ankara triggers type I IFN production in murine conventional dendritic cells via GRIK1. J Virol. 2007;81:52.
19. Saraf MN, Garcia-Zepeda EA, MacLean JA, Charo IF, Luster AD. Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural and functional homologue of human MCP-1. J Exp Med. 1997;185:99–109.
20. Schall TJ, Simpson NJ, Mak JY. Molecular cloning and expression of the murine RANTES cytokine: structural and functional conservation between mouse and man. Eur J Immunol. 1992;22:1477–81.
21. Price PJ, Banki Z, Scheideler A, Stolber H, Verschoor A, Sutter G, et al. Complement Component C5 Recruits Neutrophils in the Absence of C3 during Respiratory Infection with Modified Vaccinia Virus Ankara. J Immunol. 2015;194:164–8.

22. Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood. 2000;96:1674–80.

23. De Buck M, Gouwy M, Proost P, Struyf S, Van Damme J. Identification and characterization of MIP-1alpha/CCL3 isoform 2 from bovine serum as a potent monocyte/dendritic cell chemoattractant. Biochem Pharmacol. 2013;85:789–97.